CURRENT MANAGEMENT STRATEGIES FOR THALASSEMIA MAJOR AND THALASSEMIA MINOR

Tojiddinov Kh.S.

Authors

Tojiddinov Kh.S. Andijan State Medical Institute Republic of Uzbekistan, Andijan

Keywords:

Thalassemia major, thalassemia minor, hemoglobinopathies, blood transfusion, iron chelation, gene therapy, bone marrow transplant, genetic counseling, beta-thalassemia

Abstract

Thalassemia is a group of inherited blood disorders characterized by reduced or absent synthesis of one or more of the globin chains that make up hemoglobin. Thalassemia major and thalassemia minor represent the severe and mild ends of the clinical spectrum, respectively. While thalassemia major demands lifelong medical management, including regular blood transfusions and iron chelation therapy, thalassemia minor is typically asymptomatic and may require minimal clinical intervention. Advances in diagnostics, treatment protocols, and supportive care have significantly improved patient outcomes. This article reviews the current management strategies for both thalassemia major and minor, highlighting differences in clinical approach, the role of genetic counseling, and future directions in curative therapies such as bone marrow transplantation and gene therapy.

References

Thalassemia International Federation. (2021). Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) – 3rd Edition. TIF Publications.

Cappellini, M. D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., ... & Vichinsky, E. (2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107(9), 3455-3462. [https://doi.org/10.1182/blood-2005-08-3430]

Pennell, D. J., Porter, J. B., Cappellini, M. D., & El-Beshlawy, A. (2006). Deferiprone for the treatment of iron overload in heart and liver: 1-year results from an international clinical trial. Blood, 107(9), 3738-3744.

Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., ... & Durazzi, S. M. (1992). Bone marrow transplantation in thalassemia. The New England Journal of Medicine, 326(7), 417-421.

Angelucci, E., Matthes-Martin, S., Baronciani, D., Bernaudin, F., Bonanomi, S., Cappellini, M. D., ... & Dalle, J. H. (2014). Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Bone Marrow Transplantation, 49(6), 825–831.

Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E., Ribeil, J. A., Hongeng, S., ... & Leboulch, P. (2018). Gene therapy in patients with transfusion-dependent β-thalassemia. The New England Journal of Medicine, 378(16), 1479-1493.